"FDA Breakthrough Therapy Designation underscores both the urgent need for an effective treatment for patients and families affected by Angelman syndrome and the clinically meaningful results ...

Colin Farrell opened up to PEOPLE about his son James, who was diagnosed with Angelman syndrome. Here’s what to know about the rare neurogenetic disorder that affects 1 in 15,000 people.

The Hometown Foundation is hosting a car show for Angelman syndrome in Cheshire. Hometown Foundation hosts car show for Angelman syndrome … On-Air / Jul 3, 2025 / 10:31 AM EDT ...

Angelman syndrome is a rare condition that causes problems with growth and development. It’s caused by a genetic mutation (a change in your genes) that affects the nervous system. It’s named ...

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. The initial ...

In a conversation with People magazine in 2024, Colin Farrell opened up for the first time about his son's rare condition: ...

CARLSBAD, Calif., June 11, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the global Phase 3 REVEAL study, which is designed to ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the global Phase 3 REVEAL study, which is designed to evaluate the efficacy and safety of ...

Learn about the Aiken Newcomers' Club's support for local charities through events like a fashion show, luncheons, and silent ...

Ionis has committed to a phase 3 programme for its antisense therapy for rare genetic disorder Angelman syndrome, just weeks after Biogen decided against exercising an option to license the drug.

Ionis Pharmaceuticals has dosed the first subject in the global, randomised Phase III REVEAL trial of investigational ION582, aimed at treating individuals with Angelman syndrome (AS), a rare ...